NCT01497964已完成1 期
A Phase 2, Multicenter Study of Cabazitaxel Single Agent Administered as a 1-Hour Intravenous Infusion Every 3 Weeks to Evaluate the Safety, Tolerability and Anti-tumor Activity of Cabazitaxel in Patients With Advanced Gastric Adenocarcinoma Who Have Failed Prior Chemotherapy Regimens
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Objective Response Rate
研究概览
简要总结
Primary Objective:
- To evaluate the anti-tumor activity of cabazitaxel by assessing objective tumor response rate (ORR) at the recommended dose (RD) when administered as a single agent every 3 weeks in patients with advanced gastric adenocarcinoma who have failed prior chemotherapy regimens
Secondary Objectives:
- To determine the RD of cabazitaxel when administered as a single agent every 3 weeks
- To evaluate safety of cabazitaxel when administered as a single agent every 3 weeks
- To estimate the overall survival (OS) and progression free survival (PFS)
- To assess the pharmacokinetics (PK) profile of cabazitaxel in part 1
详细描述
Patients will be treated until disease progression, unacceptable toxicity, or patient's refusal of further study treatment. All patients will be followed during and after the study treatment until death or the end of study, whichever comes first.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Cabazitaxel
Experimental
Cabazitaxel, several dosages
干预措施: cabazitaxel XRP6258 (Drug)
结局指标
主要结局
Objective Response Rate
时间窗: Up to 2 years
次要结局
- Pharmacokinetic parameter AUClast(pre-infusion, end of infusion, 5, 15, 30 min, 1, 3, 5, 8 hours after end of infusion, 24, 48, 72, 120, 168, 216 hours after start of infusion)
- Pharmacokinetic parameter Vss(pre-infusion, end of infusion, 5, 15, 30 min, 1, 3, 5, 8 hours after end of infusion, 24, 48, 72, 120, 168, 216 hours after start of infusion)
- Overall survival (OS)(Up to a maximum of 2 years)
- Pharmacokinetic parameter: Cmax(pre-infusion, end of infusion, 5, 15, 30 min, 1, 3, 5, 8 hours after end of infusion, 24, 48, 72, 120, 168, 216 hours after start of infusion..)
- Pharmacokinetic parameter tmax(pre-infusion, end of infusion, 5, 15, 30 min, 1, 3, 5, 8 hours after end of infusion, 24, 48, 72, 120, 168, 216 hours after start of infusion..)
- Progression free survival (PFS)(Up to a maximum of 2 years)
- Number of patients with adverse events(Up to a maximum of 2 years)
- Pharmacokinetic parameter AUC(pre-infusion, end of infusion, 5, 15, 30 min, 1, 3, 5, 8 hours after end of infusion, 24, 48, 72, 120, 168, 216 hours after start of infusion)
- Pharmacokinetic parameter CL(pre-infusion, end of infusion, 5, 15, 30 min, 1, 3, 5, 8 hours after end of infusion, 24, 48, 72, 120, 168, 216 hours after start of infusion)
- Pharmacokinetic parameter t1/2z(pre-infusion, end of infusion, 5, 15, 30 min, 1, 3, 5, 8 hours after end of infusion, 24, 48, 72, 120, 168, 216 hours after start of infusion..)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With TaxanesBreast CancerNCT01693549Hellenic Cooperative Oncology Group84
已完成
2 期
A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and TaxanesRecurrent Head and Neck CancerMetastatic Head and Neck CancerNCT01620242UNICANCER31
终止
2 期
Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard TreatmentColorectal CancerNCT02204332Hospital Clinico Universitario de Santiago38
已完成
2 期
Second-line Chemotherapy in Castration Resistant Prostate CancerMetastatic Prostate CancerNCT01558219Tampere University Hospital60
已完成
2 期
Cabazitaxel in Relapsed and Metastatic NSCLCNSCLCNCT01852578Hellenic Oncology Research Group46